Nomura Holdings Inc. Increases Stake in Omnicell, Inc. (NASDAQ:OMCL)

Nomura Holdings Inc. boosted its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 85.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,463 shares of the company's stock after acquiring an additional 48,906 shares during the quarter. Nomura Holdings Inc. owned 0.23% of Omnicell worth $4,740,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in OMCL. Vanguard Group Inc. raised its holdings in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after purchasing an additional 28,573 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after acquiring an additional 737,536 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after acquiring an additional 377,883 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after acquiring an additional 699,925 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on OMCL. Benchmark lowered their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Wells Fargo & Company raised shares of Omnicell from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $31.00 to $35.00 in a report on Wednesday, May 14th. Finally, StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a report on Saturday, May 3rd. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $46.50.

Omnicell Trading Down 0.4%

NASDAQ:OMCL traded down $0.11 on Monday, reaching $27.85. The stock had a trading volume of 419,495 shares, compared to its average volume of 558,832. The company has a market cap of $1.30 billion, a price-to-earnings ratio of 103.15, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm's fifty day moving average is $31.41 and its two-hundred day moving average is $39.40. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS. Equities analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.